Influenza A viral RNA (IAV vRNA (less standardized; IAV stands for "Influenza A virus"))

Influenza A viral RNA is the single-stranded, negative-sense RNA genome of Influenza A virus, a member of the Orthomyxoviridae family[1][2]. The genome is segmented into eight RNA molecules, each of which encodes one or more viral proteins essential for the virus life cycle[1][2]. These RNA segments are bound by a viral RNA-dependent RNA polymerase complex (composed of PB1, PB2, and PA) at conserved 3′ and 5′ termini, and are coated with viral nucleoprotein (NP) to form ribonucleoprotein particles (vRNPs)[1][2][4]. Upon infection, the viral RNA serves as a template for both transcription (production of viral mRNAs via a cap-snatching mechanism) and replication (generation of complementary RNA intermediates and new genome copies)[1][2][3][4]. The structure and sequence of the vRNA, including promoter elements and secondary structures, are critical for packaging, replication, and recognition by the host cell[2]. Drugs targeting Influenza A viral RNA typically act by inhibiting the viral polymerase complex, disrupting either RNA synthesis or cap-snatching that is essential for translation of viral proteins[1][3]. Influenza A vRNA is both a molecular marker for infection and a central therapeutic target, but its high mutation rate and plasticity present challenges for intervention and resistance management.

Other names

Influenza A virus RNAInfluenza A vRNAIAV vRNAInfluenza A genomic RNANegative-sense RNA of Influenza A

Inhibition of viral RNA-dependent RNA polymerase, preventing replication and transcription of vRNA; Inhibition of endonuclease activity essential for cap-snatching and mRNA synthesis; Induction of error catastrophe by incorporating nucleoside analogs